For the Inventor, By the Inventor

Enter assignee name

Burnaby, Canada

Xenon Pharmaceuticals Inc.

Calculating rank

USPTO Granted Patents = 110

% Expired Patents = 71.8

EPO Patents = 43

Trademarks = 2

Forward Citations = 755

Loading Chart...

Loading Chart...

150 inventors (with patents filed for the assignee):

Shaoyi Sun (46 out of 49 patents)

Sultan Chowdhury (43 out of 44 patents)

Jianmin Fu (32 out of 35 patents)

4. Rajender Kamboj (32 out of 34 patents)

5. Shifeng Liu (29 out of 30 patents)

6. Serguei Sviridov (27 out of 41 patents)

7. Thilo Focken (25 out of 25 patents)

8. Alla Yurevna Zenova (25 out of 25 patents)

9. Christoph Martin Dehnhardt (25 out of 51 patents)

10. Vishnumurthy Kodumuru (25 out of 28 patents)

11. Michael Edward Grimwood (23 out of 24 patents)

12. Qi Jia (23 out of 25 patents)

13. Zaihui Zhang (21 out of 50 patents)

14. Mikhail A Chafeev (20 out of 29 patents)

15. Nagasree Chakka (18 out of 21 patents)

Core Competencies:

Therapeutic Agents

Potassium Channel Modulators

Depressive Disorders

Anhedonia Treatments

Spiro-Oxindole Compounds

Sodium Channel Activators

Sulfonamide Compounds

Bioavailability Enhancers

Benzamides

Cholesterol Modulation

Heterocyclic Inhibitors

Pyridine Derivatives

110 patents: Sort by Forward Citations

1. 12558326 - Method for treating epilepsy (2026-02-24),

2. 12319657 - Solid state crystalline forms of a selective potassium channel modulator (2025-06-03),

3. 12178811 - Methods of treating depressive disorders (2024-12-31),

4. 12171759 - Methods and uses for treating anhedonia (2024-12-24),

5. 12054486 - Pyridine derivatives and their use as sodium channel activators (2024-08-06),

6. 11957675 - Methods and uses for treating anhedonia (2024-04-16),

7. 11639351 - Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents (2023-05-02),

8. 11325902 - Benzenesulfonamide compounds and their use as therapeutic agents (2022-05-10),

9. 11299490 - Benzenesulfonamide compounds and their use as therapeutic agents (2022-04-12),

10. 11203572 - Substituted benzamides and methods of use thereof (2021-12-21),

11. 11174268 - Benzenesulfonamide compouds and their use as therapeutic agents (2021-11-16),

12. 11149002 - Therapeutic compounds and methods of use thereof (2021-10-19),

13. 11135214 - Methods for enhancing the bio availability and exposure of a voltage-gated potassium channel opener (2021-10-05),

14. 11130726 - Therapeutic compounds and methods of use thereof (2021-09-28),

15. 11091441 - Solid state crystalline forms of a selective potassium channel modulator (2021-08-17),

Company Overview

Xenon Pharmaceuticals Inc., based in Burnaby, Canada, specializes in the development of innovative therapeutic compounds aimed at addressing various medical conditions. The company focuses on creating therapeutic agents, particularly potassium channel modulators and sodium channel activators, to treat depressive disorders and anhedonia. Their research encompasses a range of advanced compounds, including spiro-oxindole and sulfonamide derivatives, with an emphasis on enhancing bioavailability and therapeutic efficacy.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

110 Patents

#5 in Burnaby

#114 in Canada

#7,168 in the World

Burnaby, Canada

Xenon Pharmaceuticals Inc.

Forward Citations = 755

150 inventors:

Shaoyi Sun (46 out of 49 patents)

Sultan Chowdhury (43 out of 44 patents)

Jianmin Fu (32 out of 35 patents)

4. Rajender Kamboj (32 out of 34 patents)

5. Shifeng Liu (29 out of 30 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Xenon Pharmaceuticals Inc.. Retrieved from https://idiyas.com/company/xenon-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…